Efinaconazole

• Description :

  Efinaconazole (KP-103) is a triazole antifungal agent and againsts T. mentagrophytes SM-110 and C. albicans ATCC 10231 with MICs of 0.0039 μg/mL and 0.00098 μg/mL, respectively[1]. Efinaconazole has a potent in vitro activity against fungal pathogens including dermatophytes, Candida and Malassezia species[1].

• Product Name Alternative :

  KP-103

• UNSPSC :

  12352005

• Hazard Statement :

  H361

• Target :

  Fungal

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/Efinaconazole.html

• Concentration :

  10mM

• Purity :

  99.84

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  C[C@@H](N1CCC(CC1)=C)[C@@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3

• Molecular Formula :

  C18H22F2N4O

• Molecular Weight :

  348.39

• Precautions :

  H361

• References & Citations :

  [1]Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57 (5) :2405-9.|[2]Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46 (7) :425-32.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [164650-44-6]